Bristol-Myers Squibb and Adnexus Therapeutics have entered a worldwide strategic alliance to discover, develop and commercialize Adnectin-based therapeutics for oncology targets. Adnexus will use its PROfusion technology on as many as six research programs to identify and deliver preclinical Adnectin candidates to BMS. BMS will be responsible for global development and commercialization activities. Adnexus retains a limited co-promotion right to the first product to receive regulatory appro...